In this episode, HBW Insight speaks to Aurélie Perrichet, regional director, Europe at the International Fragrance Association. We discussed the implications of planned revisions to the European Commission’s Classification, Labeling and Packaging (CLP) regulation, which may re-categorize biological materials as mixtures, from their current status as substances. Perrichet also speculated how the proposed change could reduce the number of available essential oils and other types of fragrance and flavor materials available.
Update: Following the recording of this podcast, the European Commission announced on 5 December a provisional agreement between the European Parliament and Council to improve the CLP revision, including a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
The evidence underpinning the “polluter pays” principle of the revised Urban Wastewater Treatment Directive - which calls on Europe's pharmaceutical industry to cough up at least 80% of the cost of updating wastewater treatment facilities - is looking increasingly shaky, according to a new report.
Ahead of a soon to be released 10-Year Health Plan for the English NHS, an alliance including PAGB calls for self-care to be “clearly recognised and supported through concrete policies that reflect its vital role in achieving the plan’s goals.”
“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”
At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.
At a recent plenary session the European Parliament adopted a resolution calling on the European Commission to “conduct a new and comprehensive assessment” of the impact of the revised Urban Wastewater Treatment Directive on the pharmaceutical sector.
At the second attempt, New Zealand’s Medicines Classification Committee supported the Rx-to-OTC switch of allopurinol (100mg and 300mg) for people suffering from gout by specifically trained pharmacists.
Germany’s Federal Institute for Risk Assessment says that there is "no evidence that people with androgenetic alopecia have special dietary needs or a special nutrient requirement.”
